GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnos Inc (OTCPK:DGNOF) » Definitions » Cyclically Adjusted Price-to-FCF

Diagnos (Diagnos) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Diagnos Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diagnos Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Diagnos's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnos Cyclically Adjusted Price-to-FCF Chart

Diagnos Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Diagnos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diagnos's Cyclically Adjusted Price-to-FCF

For the Health Information Services subindustry, Diagnos's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diagnos's Cyclically Adjusted Price-to-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Diagnos's Cyclically Adjusted Price-to-FCF falls into.



Diagnos Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Diagnos's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Diagnos's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.007/125.4675*125.4675
=-0.007

Current CPI (Dec. 2023) = 125.4675.

Diagnos Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.059 98.604 -0.075
201406 -0.108 99.473 -0.136
201409 -0.091 99.394 -0.115
201412 -0.050 98.367 -0.064
201503 -0.017 99.789 -0.021
201506 -0.033 100.500 -0.041
201509 -0.065 100.421 -0.081
201512 -0.050 99.947 -0.063
201603 -0.026 101.054 -0.032
201606 -0.035 102.002 -0.043
201609 -0.045 101.765 -0.055
201612 0.004 101.449 0.005
201703 -0.048 102.634 -0.059
201706 -0.047 103.029 -0.057
201709 -0.021 103.345 -0.025
201712 0.015 103.345 0.018
201803 -0.050 105.004 -0.060
201806 -0.006 105.557 -0.007
201809 -0.040 105.636 -0.048
201812 -0.035 105.399 -0.042
201903 -0.012 106.979 -0.014
201906 -0.016 107.690 -0.019
201909 -0.007 107.611 -0.008
201912 -0.009 107.769 -0.010
202003 -0.017 107.927 -0.020
202006 -0.005 108.401 -0.006
202009 -0.001 108.164 -0.001
202012 -0.005 108.559 -0.006
202103 -0.006 110.298 -0.007
202106 -0.007 111.720 -0.008
202109 -0.005 112.905 -0.006
202112 -0.006 113.774 -0.007
202203 -0.006 117.646 -0.006
202206 -0.007 120.806 -0.007
202209 -0.004 120.648 -0.004
202212 -0.006 120.964 -0.006
202303 -0.004 122.702 -0.004
202306 -0.007 124.203 -0.007
202309 -0.004 125.230 -0.004
202312 -0.007 125.468 -0.007

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Diagnos  (OTCPK:DGNOF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Diagnos Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Diagnos's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Diagnos (Diagnos) Business Description

Traded in Other Exchanges
Address
7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, UAE, Saudi Arabia, Mexico, Costa Rica, and others. The company's key revenue is derived from Canada.